4.7 Article

T cell-derived interferon-γ programs stem cell death in immune-mediated intestinal damage

Journal

SCIENCE IMMUNOLOGY
Volume 4, Issue 42, Pages -

Publisher

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/sciimmunol.aay8556

Keywords

-

Categories

Funding

  1. NIH [K08-HL115355, R01-HL125571, R01-HL146338, R01 CA125562, P01-CA108671, P30-CA008748]
  2. Susan and Peter Solomon Divisional Genomics Program
  3. Ludwig Center for Cancer Immunotherapy
  4. Parker Institute for Cancer Immunotherapy
  5. Anna Fuller Fund
  6. Amy Strelzer Manasevit Research Program
  7. Mochida Memorial Foundation for Medical and Pharmaceutical Research
  8. ASTCT
  9. ASBMT/ASTCT New Investigator Award
  10. American Italian Cancer Foundation
  11. WKZ fund of the UMC Utrecht
  12. Jo Kolk Study Fund Foundation
  13. Nijbakker-Morra Foundation
  14. Dutch Digestive Foundation
  15. K.F. Hein Foundation
  16. Renswoude Foundation
  17. Alexandre Suerman Stipend of the UMC Utrecht

Ask authors/readers for more resources

Despite the importance of intestinal stem cells (ISCs) for epithelial maintenance, there is limited understanding of how immune-mediated damage affects ISCs and their niche. We found that stem cell compartment injury is a shared feature of both alloreactive and autoreactive intestinal immunopathology, reducing ISCs and impairing their recovery in T cell-mediated injury models. Although imaging revealed few T cells near the stem cell compartment in healthy mice, donor T cells infiltrating the intestinal mucosa after allogeneic bone marrow transplantation (BMT) primarily localized to the crypt region lamina propria. Further modeling with ex vivo epithelial cultures indicated ISC depletion and impaired human as well as murine organoid survival upon coculture with activated T cells, and screening of effector pathways identified interferon-gamma (IFN gamma) as a principal mediator of ISC compartment damage. IFN gamma induced JAK1- and STAT1-dependent toxicity, initiating a proapoptotic gene expression program and stem cell death. BMT with IFN gamma-deficient donor T cells, with recipients lacking the IFN gamma receptor (IFN gamma R) specifically in the intestinal epithelium, and with pharmacologic inhibition of JAK signaling all resulted in protection of the stem cell compartment. In addition, epithelial cultures with Paneth cell-deficient organoids, IFN gamma R-deficient Paneth cells, IFN gamma R-deficient ISCs, and purified stem cell colonies all indicated direct targeting of the ISCs that was not dependent on injury to the Paneth cell niche. Dysregulated T cell activation and IFN gamma production are thus potent mediators of ISC injury, and blockade of JAK/STAT signaling within target tissue stem cells can prevent this T cell-mediated pathology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

Maximilian Stahl, Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy Robinson, Christopher Famulare, Christina Cho, Sean Devlin, Kamal Menghrajani, Minal A. Patel, Sheng F. Cai, Linde A. Miles, Robert L. Bowman, Mark B. Geyer, Andrew Dunbar, Zachary D. Epstein-Peterson, Erin McGovern, Jessica Schulman, Jacob L. Glass, Justin Taylor, Aaron D. Viny, Eytan M. Stein, Bartlomiej Getta, Maria E. Arcila, Qi Gao, Juliet Barker, Brian C. Shaffer, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Miguel-Angel Perales, Omar Abdel-Wahab, Ross L. Levine, Sergio A. Giralt, Yanming Zhang, Wenbin Xiao, Nidhi Pai, Elli Papaemmanuil, Martin S. Tallman, Mikhail Roshal, Aaron D. Goldberg

Summary: Measurable residual disease (MRD) is a powerful prognostic factor in acute myeloid leukemia (AML). This study aims to identify pre-treatment molecular predictors of immunophenotypic MRD clearance in AML patients. The results showed that induction chemotherapy led to different MRD responses, with 35% achieving MRD- remission, 27% achieving MRD+ remission, and 38% having persistent disease. Subsequent therapy resulted in MRD conversion in 34% of MRD+ patients and 26% of patients with persistent disease. Specific gene mutations and karyotypic abnormalities were found to be associated with high or low rates of MRD- remission. Patients with fewer individual clones were more likely to achieve MRD- remission. Furthermore, the study demonstrated that achieving MRD- prior to allogeneic stem cell transplant (allo-SCT) was associated with favorable outcomes. Therefore, the inclusion of patients with specific baseline mutational patterns and high clone numbers in clinical trials should be considered.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Oncology

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms

Lindsay M. Gurska, Rachel Okabe, Alexandra Schurer, Meng Maxine Tong, Mark Soto, Daniel Choi, Kristina Ames, Shira Glushakow-Smith, Allison Montoya, Ellen Tein, Linde A. Miles, Haiying Cheng, Pamela Hankey-Giblin, Ross L. Levine, Swati Goel, Balazs Halmos, Kira Gritsman

Summary: The study found that crizotinib could suppress the activation of the JAK/STAT signaling pathway and decrease the disease burden of MPN. Additionally, crizotinib could overcome the persistence of JAK inhibitors by disrupting the interaction between RON kinase and JAK2. This research suggests that crizotinib should be further explored as a potential treatment for patients with MPN.

CLINICAL CANCER RESEARCH (2023)

Article Gastroenterology & Hepatology

Rifaximin stimulates nitrogen detoxification by PXR-independent mechanisms in human small intestinal organoids

Koos de Wit, Ulrich Beuers, Anna Mukha, Edwin C. A. Stigter, M. Can Gulersonmez, Jose Ramos M. Pittol, Sabine Middendorp, R. Bart Takkenberg, Saskia W. C. van Mil

Summary: This study investigated the effects of rifaximin on the biotransformation machinery in the small intestine, uncovering its role in promoting ammonia detoxification by increasing glutamine and asparagine concentrations.

LIVER INTERNATIONAL (2023)

Article Multidisciplinary Sciences

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells

Jerome Fortin, Ming-Feng Chiang, Cem Meydan, Jonathan Foox, Parameswaran Ramachandran, Julie Leca, Francois Lemonnier, Wanda Y. Li, Miki S. Gams, Takashi Sakamoto, Mandy Chu, Chantal Tobin, Eric Laugesen, Troy M. Robinson, Annick You-Ten, Daniel J. Butler, Thorsten Berger, Mark D. Minden, Ross L. Levine, Cynthia J. Guidos, Ari M. Melnick, Christopher E. Mason, Tak W. Maka

Summary: Mutations in IDH1, IDH2, and TET2 genes are commonly observed in myeloid neoplasms. These mutations have unexpected, distinct effects on hematopoietic stem and progenitor cells, contrary to previous expectations. Understanding these molecular alterations could lead to the development of more effective, genotype-specific therapies.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Editorial Material Oncology

Oncogenic IDH1 Mutation Imparts Therapeutically Targetable Metabolic Dysfunction in Multiple Tumor Types

Troy M. Robinson, Ross L. Levine

Summary: In this study, the researchers used mass spectrometry metabolomics, stable isotope labeling, and functional studies to investigate metabolic vulnerabilities in cancers with mutations in isocitrate dehydrogenase (IDH). They provide compelling evidence that dysregulated lipid synthesis is a synthetic lethal target in cancers with IDH1 mutations, but not IDH2 mutations.

CANCER DISCOVERY (2023)

Article Public, Environmental & Occupational Health

Routine saliva testing for SARS-CoV-2 in children: Methods for partnering with community childcare centers

Erica J. Rayack, Hibah Mahwish Askari, Elissa Zirinsky, Sarah Lapidus, Hassan Sheikha, Chikondi Peno, Yasaman Kazemi, Devyn Yolda-Carr, Chen Liu, Nathan D. Grubaugh, Albert I. Ko, Anne L. Wyllie, Erica S. Spatz, Carlos R. Oliveira, Amy K. Bei

Summary: In the early phase of the COVID-19 pandemic, a PCR-based COVID-19 surveillance program was established in childcare facilities to collect actionable public health data and aid in the resumption of standard operations. This study describes the development of a saliva testing program for children and childcare center staff, providing a feasible method of asymptomatic screening and symptomatic testing. The study emphasizes the importance of cooperation between childcare centers, parents/guardians, and staff to mitigate COVID-19 transmission.

FRONTIERS IN PUBLIC HEALTH (2023)

Article Hematology

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Andrew J. Dunbar, Dongjoo Kim, Min Lu, Mirko Farina, Robert L. Bowman, Julie L. Yang, Young Park, Abdul Karzai, Wenbin Xiao, Zach Zaroogian, Kavi O'Connor, Shoron Mowla, Francesca Gobbo, Paola Verachi, Fabrizio Martelli, Giuseppe Sarli, Lijuan Xia, Nada Elmansy, Maria Kleppe, Zhuo Chen, Yang Xiao, Erin McGovern, Jenna Snyder, Aishwarya Krishnan, Corrine Hill, Keith Cordner, Anouar Zouak, Mohamed E. Salama, Jayden Yohai, Eric Tucker, Jonathan Chen, Jing Zhou, Timothy McConnell, Anna R. Migliaccio, Richard Koche, Raajit Rampal, Rong Fan, Ross L. Levine, Ronald Hoffman

Summary: Inflammatory signaling is crucial in the development of myelofibrosis (MF), a type of cancer. Recent studies have identified the involvement of JAK/STAT and NF-kappa B signaling in MF progression. This study further explores the role of CXCL8/CXCR2 signaling in MF pathogenesis, and highlights its potential as a therapeutic target.

BLOOD (2023)

Article Oncology

Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis

James M. Foran, Zhuoxin Sun, Catherine Lai, Hugo F. Fernandez, Larry D. Cripe, Rhett P. Ketterling, Janis Racevskis, Selina M. Luger, Elisabeth Paietta, Hillard M. Lazarus, Yanming Zhang, John M. Bennett, Ross L. Levine, Jacob M. Rowe, Mark R. Litzow, Martin S. Tallman

Summary: This study examined the association of obesity with AML and its impact on clinical outcomes. The results showed that obesity was associated with certain clinical and genetic features of AML, but did not affect patient survival.

CANCER (2023)

Article Oncology

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J. Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis

Summary: This study evaluated the efficacy of entospletinib, an oral inhibitor of spleen tyrosine kinase, combined with decitabine in patients with acute myeloid leukemia (AML) who have poor prognosis. The combination showed some activity and acceptable tolerance, but the complete remission rates were low and overall survival was short.

CANCER (2023)

Article Endocrinology & Metabolism

Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study

Laura Boucai, Ryan N. Ptashkin, Ross L. Levine, James A. Fagin

Summary: In this prospective cohort study, the effects of therapeutic radioactive iodine (RAI) on clonal hematopoiesis (CH) were examined. The results showed no increase in CH in patients treated with RAI over a 2-year follow-up period. It was also found that the presence of CH was associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.

CLINICAL ENDOCRINOLOGY (2023)

Article Gastroenterology & Hepatology

Pathology of Acute and Acute-on-Chronic Liver Failure

Cameron Beech, Chen Liu, Xuchen Zhang

CLINICS IN LIVER DISEASE (2023)

Article Multidisciplinary Sciences

MEN1 mutations mediate clinical resistance to menin inhibition

Florian Perner, Eytan M. M. Stein, Daniela V. V. Wenge, Sukrit Singh, Jeonghyeon Kim, Athina Apazidis, Homa Rahnamoun, Disha Anand, Christian Marinaccio, Charlie Hatton, Yanhe Wen, Richard M. M. Stone, David Schaller, Shoron Mowla, Wenbin Xiao, Holly A. A. Gamlen, Aaron J. J. Stonestrom, Sonali Persaud, Elizabeth Ener, Jevon A. A. Cutler, John G. G. Doench, Gerard M. M. McGeehan, Andrea Volkamer, John D. D. Chodera, Radoslaw P. Nowak, Eric S. S. Fischer, Ross L. L. Levine, Scott A. A. Armstrong, Sheng F. F. Cai

Summary: Chromatin-binding proteins are important regulators of cell state in haematopoiesis. Clinical trials have shown that the menin inhibitor revumenib can treat leukaemia with KMT2Ar or NPM1 mutations. However, acquired resistance to menin inhibition may be caused by somatic mutations in the MEN1 gene.

NATURE (2023)

Article Biochemistry & Molecular Biology

Clonal hematopoiesis, aging and Alzheimer's disease

Pablo Sanchez Vela, Jennifer J. J. Trowbridge, Ross L. L. Levine

Summary: New data reveals the surprising association between clonal hematopoiesis and protection from Alzheimer's disease, highlighting the need for future studies to unravel the complex mechanisms underlying the role of clonal hematopoiesis in tissue-disease contexts and aging-associated diseases.

NATURE MEDICINE (2023)

Article Hematology

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

Umeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, Bac Viet Le, Marie-Christine Caron, Anna-Mariya Kukuyan, Katherine Sullivan-Reed, Paulina Podszywalow-Bartnicka, Kumaraswamy N. Chitrala, Jessica Atkins, Malgorzata Drzewiecka, Wanjuan Feng, Joe Chan, Srinivas Chatla, Konstantin Golovine, Jaroslav Jelinek, Tomasz Sliwinski, Jayashri Ghosh, Ksenia Matlawska-Wasowska, Gurushankar Chandramouly, Reza Nejati, Mariusz Wasik, Stephen M. Sykes, Katarzyna Piwocka, Emir Hadzijusufovic, Peter Valent, Richard T. Pomerantz, George Morton, Wayne Childers, Huaqing Zhao, Elisabeth M. Paietta, Ross L. Levine, Martin S. Tallman, Hugo F. Fernandez, Mark R. Litzow, Gaorav P. Gupta, Jean-Yves Masson, Tomasz Skorski

Summary: Leukemia cells accumulate DNA damage, but altered DNA repair mechanisms protect them from apoptosis. Formaldehyde generated by serine/1-carbon cycle metabolism contributes to the accumulation of toxic DNA-protein crosslinks (DPCs) in leukemia cells. Oncogenic tyrosine kinases (OTKs) enhance the expression of DNA polymerase theta (POL theta) to repair DPC-containing DNA double-strand breaks. Inhibition of POL theta can be an effective therapeutic strategy for leukemia.

BLOOD (2023)

Article Oncology

PU.1-Dependent Enhancer Inhibition Separates Tet2-Deficient Hematopoiesis from Malignant Transformation

Maria M. Aivalioti, Boris A. Bartholdy, Kith Pradhan, Tushar D. Bhagat, Aliona Zintiridou, Jong Jin Jeong, Victor J. Thiruthuvanathan, Mario Pujato, Aditi Paranjpe, Chi Zhang, Ross L. Levine, Aaron D. Viny, Amittha Wickrema, Amit Verma, Britta Will

Summary: This study reveals the collaborative role of Tet2 and PU.1 in suppressing leukemogenesis and the significance of a methylation-sensitive PU.1-dependent gene network in myeloid leukemia.

BLOOD CANCER DISCOVERY (2022)

No Data Available